The Role of Fragile Sites in Sporadic Papillary Thyroid Carcinoma by Dillon, Laura W. et al.
Hindawi Publishing Corporation
Journal of Thyroid Research
Volume 2012, Article ID 927683, 12 pages
doi:10.1155/2012/927683
Review Article
TheRoleofFragileSitesinSporadicPapillaryThyroidCarcinoma
LauraW.Dillon,1 ChristineE. Lehman,2 andYuh-HwaWang1
1Department of Biochemistry, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1016, USA
2Department of Cancer Biology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157-1016, USA
Correspondence should be addressed to Yuh-Hwa Wang, ywang@wakehealth.edu
Received 14 March 2012; Accepted 18 April 2012
Academic Editor: P. Beck-Peccoz
Copyright © 2012 Laura W. Dillon et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Theincidenceofthyroidcancerisincreasing,especiallypapillarythyroidcarcinoma(PTC),makingitcurrentlythefastest-growing
canceramongwomen.Reasonsforthisincreaseremainunclear,butseveralriskfactorsincludingradiationexposureandimproved
detection techniques have been suggested. Recently, the induction of chromosomal fragile site breakage was found to result in the
formation of RET/PTC1 rearrangements, a common cause of PTC. Chromosomal fragile sites are regions of the genome with
a high susceptibility to forming DNA breaks and are often associated with cancer. Exposure to a variety of external agents can
induce fragile site breakage, which may account for some of the observed increase in PTC. This paper discusses the role of fragile
site breakage in PTC development, external fragile site-inducing agents that may be potential risk factors for PTC, and how these
factors are especially targeting women.
1. Introduction
The incidence of thyroid cancer is dramatically rising in
the Unites States and other countries. Thyroid cancer has
increased steadily in the Unites States over the past several
decades, and according to data from the National Can-
cer Institute’s Surveillance, Epidemiology and End Results
(SEER) database, incidences are now nearly three times that
of the early 1970s [1–3]. Furthermore, for unknown reasons,
thyroid cancer is three times more prevalent in women than
men. Thyroid cancer is the sixth most common type of
cancer among women and increasing more rapidly than any
other cancer. The American Cancer Society estimates that
56,460 new cases of thyroid cancer (43,210 in women and
13,250inmen)willbediagnosedintheUnitedStatesin2012,
with approximately 80% of patients below 65 years old [4].
The recent upsurge in thyroid cancer is not well under-
stood. Rates of thyroid cancer diagnoses have increased the
most among small (≤2cm) thyroid nodules, which may be
explained by the use of thyroid ultrasound for diagnosis
beginning in the 1980s [2, 5]. However, it is believed that the
increase in thyroid cancer is not solely based on diagnostic
methods [6], but due to changes in other risk factors as
well [7] .O n ep o s s i b l ec o n t r i b u t o r yr i s kf a c t o ri se x p o s u r et o
ionizing radiation [8], either from external radiation, such as
X-rays and γ-radiation, or internal radiation, from ingestion
or inhalation of radioiodine. Increases in thyroid cancer have
been well documented following exposure to high doses of
radiation during medical procedures or following nuclear
bomb explosions or nuclear reactor fallouts [9]. However,
exposure to low doses of radiation from routine diagnostic
X-ray procedures and in the workplace does not increase the
risk of thyroid cancer development [9], suggesting radiation
exposure is not the only risk factor. An increased body mass
index (BMI) is also positively associated with thyroid cancer
in both women and men [10], suggesting obesity is another
risk factor for thyroid cancer.
Recently, it was observed that the chemical induction
of DNA breakage at chromosomal fragile sites could result
in the formation of RET/PTC1 rearrangements, one com-
mon mutation observed in papillary thyroid carcinoma
(PTC) [11]. Chromosomal fragile sites are regions of the
genome prone to DNA breakage and often coincide with
mutations observed in cancer [12]. Exposure to a variety
of external agents, including dietary, environmental, and
chemotherapeuticagents,caninducebreakageatfragilesites.2 Journal of Thyroid Research
Therefore, exposure to fragile-site-inducing conditions may
be an additional risk factor for thyroid cancer development,
speciﬁcally PTC. Interestingly, the increasing rates of thyroid
cancerarealmostentirelyduetoanincreaseinPTC[2,3,13].
In this paper, we will discuss the potential role of fragile sites
inPTCandtheexternalfragile-site-inducing agentsthatmay
be a risk factor for thyroid cancer.
2. FragileSitesandCancer
2.1. Chromosomal Fragile Sites. Chromosomal fragile sites
are nonrandom loci that can be observed as gaps or breaks
on metaphase chromosomes under conditions that partially
inhibit DNA replication [14]. Fragile sites can further be
deﬁned as common or rare, based on the frequency of
their occurrence in the population. Rare fragile sites consist
of repeated sequence motifs, such as trinucleotide repeats,
which are present in less than 5% of the population and are
inherited in a Mendelian manner [15]. In contrast, common
fragile sites are present in all individuals and therefore are a
normal component of chromosomal architecture [16].
Fragilesitescanbeobservedinculturethroughtreatment
with various chemicals. The majority of common fragile
sites can be induced by aphidicolin (APH), an inhibitor of
DNA polymerases α, β,a n dδ [17, 18]. Induction of other
common fragile sites has been observed following treatment
withbromodeoxyuridine(BrdU)or5-azacytidine[19].Most
rare fragile sites are expressed through the removal of
folate, while others show induction following treatment with
distamycin-A or BrdU [15]. Additionally, common fragile
site breakage can be induced or enhanced through exposure
to various dietary or environmental chemicals, including
chemotherapeutic agents [12] (details in Section 4).
Unlike rare fragile sites, no known consensus sequence
exists for common fragile sites. However, several characteris-
ticshavebeenobservedatmanycommonfragilesitesstudied
to date. These include being located within large genes [19]
and within regions of the genome that replicate late in the
S-phase [20–23]. Also, several fragile sites contain highly
ﬂexible AT-rich sequences [24, 25] and are predicted to
form stable DNA secondary structures [24, 26, 27]. Also, the
ATR (ataxia-telangiectasia and Rad3-Related-) dependent
DNA repair pathway, which responds to stalled or collapsed
replication forks, is known to be vital for maintaining
stability at fragile sites [28–30]. One model for common
fragile site breakage is that, under conditions of replication
stress, stable DNA secondary structures form at fragile sites,
blocking replication fork progression. If the ATR pathway
fails to properly repair these stalled replication forks, this
could result in DNA breakage within these regions. In
addition to replication fork stalling, paucity of replication
initiation in fragile site regions [31] and the presence of
transcription-derived R-loops during DNA replication of
fragile sites [32] may also be involved in the mechanism of
fragility.
2.2. Role of Fragile Sites in Cancer. Studies over the past
severaldecadeshaveshownacorrelationbetweenfragilesites
and cancer-speciﬁc chromosomal aberrations [33]. Many of
the genes identiﬁed within fragile sites are known tumor
suppressor genes or oncogenes [34]. Fragile sites have been
identiﬁed as hot spots for sister chromatid exchange [35],
viral integrations [36–41], and gene ampliﬁcations [42–45]
in tumor cells. Additionally, mutational signatures of some
unexplained homozygous deletions observed in cancer cell
lines match those at fragile sites [46].
A comprehensive examination of all known simple
chromosomal translocations in cancer revealed that 52% of
these recurrent translocations had at least one breakpoint
located within a fragile site [47]. Speciﬁcally, 40% of
translocations had breakpoints within one gene located in
a fragile site, while an additional 12% of translocations
had breakpoints within both genes located in fragile sites
(Figure 1). Furthermore, 65% of the breakpoints identiﬁed
within fragile sites were within common—not rare—fragile
sites, conferring a genetic risk among all individuals. Since
thisstudyonlyfocusedonsimpletranslocationsbetweentwo
genes and not the participation of fragile sites in other more
complex genomic rearrangements, the association of fragile
s i t e sw i t hb r e a k p o i n t si nc a n c e rm a yp r o v et ob eg r e a t e rt h a n
estimated in this study.
In addition to the correlation between fragile sites and
regions of the genome mutated in cancer, two studies
have investigated the direct contribution of fragile site
breakage to the formation of cancer-speciﬁc chromosomal
aberrations. Durkin et al. observed deletions within the
tumor suppressor gene FHIT, located within the most active
common fragile site FRA3B, following treatment of human-
mouse chromosome 3 somatic hybrid cells with APH. These
deletions were consistent with those observed in esophageal,
breast, and lung cancers [48]. Recently, we observed the
formation of RET/PTC1 rearrangements, a translocation
commonly observed in PTC, in a human thyroid epithelial
cell line following treatment with the fragile-site-inducing
chemicals APH, BrdU, and 2-aminopurine (2-AP) [11].
Individuals genetically predisposed to forming cancer
also have higher levels of fragile site breakage. For example,
Seckel syndrome—a rare genetic disorder in which patients
exhibithighlevelsofchromosomalinstabilityandcancer—is
causedbylowexpressionoftheDNArepairproteinATR,due
to a hypomorphic mutation in the ATR gene [49]. Cells from
patientswithSeckelsyndromehavesigniﬁcantlyhigherlevels
of APH-induced fragile site breakage compared to normal
individuals [50]. Another rare genetic disorder, Fanconi
anemia (FA), is the result of mutations in various proteins
involved in the FA double-strand DNA repair pathway.
Patients with FA have elevated levels of chromosomal break-
age and cancer [51]. Chromosomal breakpoints in blood
l y m p h o c y t e sf r o mF Ap a t i e n t sa r ep r e f e r e n t i a l l yl o c a t e di n
fragile sites [52], and APH-induced fragile site breakage is
signiﬁcantly increased among these patients [53]. Proteins in
both the ATR and FA DNA repair pathways are important in
maintaining stability at fragile sites [12]. The WRN protein,
which is phosphorylated by and colocalizes with ATR in
response to replication fork arrest [54], is also vital for
maintaining common fragile site stability, and this function
requires WRN helicase activity [55]. Mutations in WRN canJournal of Thyroid Research 3
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Figure 1: Percentage of breakpoints in genes involved in cancer-
causing simple recurrent chromosomal translocations located
within fragile sites.
result in Werner syndrome, which is an autosomal recessive
premature aging disease where individuals have a high
predisposition to cancer development [56]. Interestingly,
Japanese Werner syndrome patients have much higher levels
of thyroid cancer, including PTC, than normal Japanese
individuals [57]. Together these provide extreme examples
for a genetic predisposition for fragile site breakage and
cancer development.
Together these previous studies provide a strong link
between fragile sites and cancer, whereby exposure to fragile-
site-inducing conditions and/or a genetic predisposition
couldattributetothedevelopmentofvarioustypesofcancer.
3. FragileSiteInstabilityinPTC
3.1. RET/PTC Translocations in PTC. PTC is primarily
responsible for the upsurge in thyroid cancer rates [3].
One mutation commonly observed in PTC is RET/PTC
rearrangements, in which the RET oncogene translocates
with a variety of genes that are constitutively expressed in
the thyroid. RET (rearranged during transfection) encodes
for a cell membrane receptor tyrosine kinase that responds
to ligands of the glial cell line-neurotropic factor (GDNF)
family, activating cell growth and survival pathways [58].
Expression of RET in the thyroid is high in neural-crest-
derived C cells but not in follicular cells, where RET/PTC
rearrangements result in its activation through expression of
fusion proteins leading to tumorigenesis.
While prevalence of RET/PTC rearrangements is variable
among diﬀerent studies, overall these translocations are
found in 30–40% of adult and 50–60% of pediatric PTC
tumors [59]. To date, 12 RET/PTC rearrangements have
been reported, all involving RET [60]. The two most
common subtypes are RET/PTC1 and RET/PTC3,w h e r e
RET is translocated with CCDC6 and NCOA4,r e s p e c t i v e l y
[61]. One known risk factor for RET/PTC rearrangement
formation is exposure to radiation, where the incidence
of RET/PTC rearrangements in PTC patients increases to
60–70% regardless of age [59]. RET/PTC3 rearrangements
have shown a strong correlation with radiation exposure,
where multiple studies indicated these translocations in
63–75% of radiation-induced RET/PTC-positive pediatric
PTCtumors[62–65].Incontrast,RET/PTC1rearrangements
have been observed in 50–71% of RET/PTC-positive spo-
radic PTC tumors, while RET/PTC3 rearrangements were
only observed in 13–42% of tumors [62, 66–68].
Spatial proximity of RET/PTC-participating genes is one
of the factors contributing to cell speciﬁcity of the disease
[69]. The interphase distance between RET and CCDC6 is
shorter in normal human thyroid cells than in peripheral
blood lymphocytes or in normal mammary epithelial cells
[69]. Further, RET, CCDC6,a n dNCOA4 are all located on
chromosome 10 and despite the predicted distance of the
genes based on their location along chromosome 10, RET
is located closer to NCOA4 and CCDC6 than would be
expected, during interphase in normal human thyroid cells
[70].
RET, CCDC6,a n dNCOA4, the genes participating in
RET/PTC1 and RET/PTC3 rearrangements, are all located
within common fragile sites. RET and NCOA4 are both
located within the same APH-inducible common fragile site,
FRA10G, while CCCD6 is located within the BrdU-induced
common fragile site FRA10C. The location of these genes
within fragile sites, the unexplained nature of sporadic PTC
tumors containing translocations of these genes, and the
increasing incidence of PTC tumors suggest that fragile site
breakage may contribute to sporadic RET/PTC rearrange-
ments.
3.2. Fragile-Site-Inducing Conditions Produce DNA Breaks
in RET/PTC Rearrangement-Participating Genes and Gen-
erate RET/PTC1 Translocations. The idea that fragile site
breakage contributes to RET/PTC rearrangement formation
was directly demonstrated in our recent publication [11].
In this study, we ﬁrst examined whether RET, CCDC6,
and NCOA4 are true fragile sites, for example, sensitive
to fragile-site-inducing conditions using ﬂuorescence in
situ hybridization (FISH). HTori-3 cells, a human thyroid
epithelial cell line devoid of RET/PTC rearrangements, were
treated with combinations of fragile-site-inducing chemicals
known to induce the fragile sites containing the RET/PTC
genes, and chromosomal breakage was measured at each
gene based on the percent break of the corresponding FISH
probe (Figure 2(a)). The presence of RET and NCOA4
in the APH-induced common fragile site FRA10G was
investigated by treating HTori-3 cells with APH and 2-AP.
The chemical 2-AP is a general inhibitor of ATR kinase,
shown to increase fragile site breakage at FRA3B [29].
This treatment produced signiﬁcant levels of chromosomal
breakage at RET and only low levels at NCOA4 and CCDC6,
indicating that RET and not NCOA4 is contained within
FRA10G. The presence of CCDC6 within the BrdU-induced
common fragile site FRA10C was tested by treating HTori-
3 cells with BrdU and 2-AP. High levels of breakage were
observed at CCDC6, but only low levels at RET and NCOA4
(Figure 2(a)), conﬁrming the location of CCDC6 within
FRA10C. These observations demonstrated that fragile-site-
inducing chemicals consistent with the mode of induction
for each fragile site can induce DNA breakage at RET4 Journal of Thyroid Research
and CCDC6 in thyroid cells. Furthermore, when HTori-
3 cells were treated with all three chemicals at once, high
levels of breakage were observed within RET and CCDC6
simultaneously (Figure 2(a)), indicating the possibility of
RET/PTC1 chromosomal rearrangements.
The major breakpoint cluster region of RET observed
in RET/PTC tumor cells is intron 11 [71]. Using ligation-
mediated-PCR (LM-PCR), we showed that APH treatment
induced DNA breakage within intron 11 of RET in HTori-3
c e l l s .T h er a t eo fD N Ab r e a k a g ea tRET intron 11 with APH
treatment was signiﬁcantly greater than without treatment
(P = 0.010, Figure 2(b)). Furthermore, APH-induced break-
age in HTori-3 cells was speciﬁc to fragile sites, where APH
treatment also induced DNA breakage within FHIT,l o c a t e d
within the APH-inducible common fragile site FRA3B,
but not in the nonfragile 12p12.3 region or in the G6PD
gene, located within the non-APH-inducible rare folate-
sensitive fragile site FRAXF (Figure 2(b)). Furthermore, the
breakpoints located within intron 11 of RET were located
near previously identiﬁed breakpoints in RET/PTC tumors
[72, 73]. These results suggest that fragile site breakage
within RET could lead to the generation of oncogenic fusion
transcripts.
The generation of RET/PTC rearrangements following
exposure to fragile-site-inducing chemicals was directly
tested by treating HTori-3 cells with APH, BrdU, and 2-
AP, and the presence of fusion RET/PTC1 or RET/PTC3
mRNA transcripts was detected by reverse transcription-
PCR (RT-PCR). No RET/PTC rearrangements were detected
withouttreatment,indicatinganextremelylowlevelofspon-
taneous rearrangement (Figure 2(c)). However, treatment
with fragile-site-inducing chemicals resulted in RET/PTC1
rearrangement events with a frequency of one in 106 cells,
but no RET/PTC3 rearrangement events (Figure 2(c)). These
results were consistent with the chromosomal breakage
observed in FISH analyses, where only the RET/PTC1 genes
RET and CCDC6 exhibited high levels of breakage following
treatment.
The data from this study provide direct evidence that
fragile sites are involved in the generation of RET/PTC1 rear-
rangements in sporadic PTC tumors. Exposure to external
factors that can induce fragile site breakage may play a role in
the increasing incidence of PTC.
4. Effect of ExternalFactors on
FragileSiteBreakage
Aside from classic fragile-site-inducing chemicals like APH,
DNA breakage at common fragile sites has been observed
following exposure to many external agents, including
dietary, environmental, and chemotherapeutic compounds
(Table 1). Variability in fragile site breakage has been
observed among individuals [87], with high levels being
associated with cancer patients [88]. These variances may
reﬂect diﬀering exposures to external fragile-site-inducing
agents, and such exposure may predispose an individual to
a variety of cancers, including PTC.
4.1. Environmental and Dietary Fragile-Site-Inducing/En-
hancing Chemicals. Numerous dietary and environmental
chemicals can induce or enhance fragile site breakage
(Table 1). Caﬀeine and ethanol are two dietary agents that
can signiﬁcantly increase the rate of fragile site breakage.
Caﬀeine, an inhibitor of phosphoinositide 3-kinase-related
kinases, including ATR and ATM (ataxia telangiectasia
mutated), signiﬁcantly enhances fragile site breakage in
combination with APH or ﬂuorodeoxyuridine (FUdR) [76,
77]. Similarly, ethanol enhances APH-induced fragile site
breakage [80]. Cells from chronic alcohol users have an
increased frequency of fragile site breakage compared to
nondrinkers, which suggests that long-term alcohol use can
induce fragile site expression [81].
Exposure to cigarette smoke, pesticides, or hypoxic
conditions can also increase susceptibility to fragile site
breakage. Peripheral blood lymphocytes from cigarette
smokers have signiﬁcantly greater levels of APH-induced
fragile site breakage compared to nonsmokers [78]. Inter-
estingly, peripheral blood lymphocytes from non-smokers
and patients with small cell lung cancer who have stopped
smoking both display lower levels of fragile site breakage
following APH treatment than active smokers, suggesting
this risk factor is reversible [79]. Individuals exposed to
pesticides through occupational work, such as pesticide
sprayers or ﬂower collectors working in greenhouses, have
increased levels of APH-induced fragile site breakage in their
blood lymphocytes compared to control individuals, and
theseresultspersistedevenayearlater[83–85].Furthermore,
the pesticide-induced breakage was located within fragile
sitescontainingbreakpointsobservedinnon-Hodgkin’slym-
phoma and leukemia; consistent with this ﬁnding, increasing
rates of hematopoietic cancers have been linked to pesticide
exposure [89, 90]. Hypoxic conditions also enhance fragile
site breakage with or without APH treatment in CMA32
Chinese hamster cells [82].
Dietary and environmental agents, carbon tetrachloride,
dimethyl sulfate, benzene, and diethylnitrosamine all can
induce fragile site breakage [75]. Carbon tetrachloride is
used in refrigerants, pesticides, and industrial and man-
ufacturing processes [91]. Formerly, this compound was
used in cleaning ﬂuids and ﬁre extinguishers, but has
since been banned from home use due to its carcinogenic
properties. An increased risk of non-Hodgkin’s lymphoma
has been reported among individuals working in manu-
facturing, industrial, and laboratory jobs in which they
are exposed to carbon tetrachloride. Dimethyl sulfate is
used to manufacture organic chemicals including pesticides,
dyes, drugs, perfumes, fabric softeners, and adhesives [91].
Dimethyl sulfate was also formerly used as a chemical
weapon. Occupational exposure to this compound has been
linked to cancers of the eye, bronchus, and lung.
Benzeneisaknownhumancarcinogenfoundingasoline,
pesticides, cigarette smoke, and industrial emissions and is
a common contaminant detected in food and water [91].
According to the US Department of Health and Human
Services,halfofthenationalexposuretobenzenecomesfrom
cigarette smoke, a known fragile-site-enhancing agent. The
optimal concentrations of benzene (500μg/mL) to induceJournal of Thyroid Research 5
Table 1: External Fragile Site-Inducing/Enhancing Agents.
Agents Applications References
Dietary and environmental
Atenolol Hypertension drug [74]
Benzene Cigarette smoke, gasoline, pesticides, food, water [75]
Caﬀeine Dietary agent [76, 77]
Carbon tetrachloride Refrigerants, pesticides [75]
Cigarette smoke Dietary and environmental agent [78, 79]
Diethylnitrosamine Cigarette smoke, pesticides, food, beverage [75]
Dimethyl sulfate Dyes, drugs, perfumes, pesticides [75]
Ethanol Dietary agent [80, 81]
Hypoxia Low oxygen, tumor microenvironment [82]
Pesticides Dietary and environmental agent [83–85]
Chemotherapeutics
5-Azacytidine Myelodysplastic syndrome, leukemia [75]
Actinomycin D Sarcoma, Wilms’ tumor, germ cell, testicular, Melanoma, neuroblastoma, retinoblastoma [75]
Bleomycin Squamous cell, melanoma, sarcoma, testicular, Hodgkin’s and non-Hodgkin’s lymphoma [75]
Busulfan Chronic myelogenous leukemia [75]
Camptothecin Colon, rectal [86]
Chlorambucil Chronic lymphocytic leukemia, Hodgkin’s and non-Hodgkin’s lymphoma, breast, ovarian,
testicular
[75]
Cytosine arabinoside Leukemia, lymphoma [75]
Floxuridine Colon, kidney, stomach [75]
Methotrexate Breast, head and neck, lung, stomach, esophageal, sarcoma, non-Hodgkin’s lymphoma, acute
lymphoblastic leukemia
[75]
fragile sites are relevant. Smoke from a smoldering cigarette
yields 345–653μg of benzene, and the average exposure for
one hour of driving or riding in a car is about 40μgb e n z e n e
(even greater in highly congested areas) [91]. Therefore,
the general population is exposed to a level of benzene
comparable to the amount able to induce fragile sites,
especially under long-term exposure.
Exposure to benzene due to occupation or geographic
location has been linked to leukemia. Recently, Pellegriti et
al. observed a signiﬁcantly higher prevalence of PTC in the
Sicilian province of Catania, located near the Mount Etna
volcano, compared to other provinces, which could not be
explained by industrial pollution or mild iodine deﬁciencies
[92]. The authors suggest that exposure to environmental
factors associated with the Mount Etna volcano may be
responsible. Benzene can form following the incomplete
combustion of organic materials in volcanoes and forest
ﬁres [93]a n dh a sb e e nd e t e c t e di nl a v ag a s e se m i t t e df r o m
Mount Etna [94], suggesting fragile site breakage due to
benzene exposure may contribute to the increasing incidence
of PTC in Catania. Furthermore, we have observed that
treatment of HTori-3 cells with levels of benzene previously
shown to induce fragile sites [75] results in a statistically
signiﬁcant increase in DNA breakage within RET intron 11,
and this breakage was speciﬁc to fragile sites (unpublished
observations).
Diethylnitrosamine (DEN) is found in pesticides,
cigarette smoke, industrial pollution, drinking water, and
foods and beverages [91]. DEN was previously used as a
gasoline and lubricant additive, antioxidant, stabilizer in
plastics, and in other manufacturing processes. Although
there are no studies relating exposure to DEN with can-
cer susceptibility in humans, many studies in laboratory
animals have shown that DEN exposure can result in the
development of various tumors [91]. As with benzene,
we found that DNA breakage within RET intron 11 was
signiﬁcantly increased in HTori-3 cells following exposure to
dosagesofDENpreviouslyshowntoinducefragilesites[75],
and this breakage was speciﬁc to fragile sites (unpublished
observations).
Atenolol is a common β-blocker used to treat hyperten-
sion, and peripheral blood lymphocytes from hypertensive
patients taking this drug exhibit higher levels of chromatid
and chromosomal breaks than normal individuals not taking
atenolol; these breaks were preferentially located at fragile
sites [74]. Furthermore, blood lymphocytes from patients
taking atenolol have signiﬁcantly more micronuclei than
normal patients [95]. Although antihypertensive drugs have6 Journal of Thyroid Research
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Figure 2: Fragile-site-inducing chemicals generate DNA breakage within RET/PTC genes and RET/PTC1 rearrangements. (a) Percentage of
chromosomes showing disruption of RET, NCOA4,a n dCCDC6 following treatment of HTori-3 cells with fragile-site-inducing chemicals
as detected by FISH. Error bars represent standard deviation. (b) The level of DNA breakage in HTori-3 cells at RET intron 11,
FHIT intron 4, 12p12.3, and G6PD with or without APH treatment was detected using LM-PCR. (c) The formation of RET/PTC1 or
RET/PTC3 rearrangement events was detected in HTori-3 cells using RT-PCR following treatment with fragile-site-inducing chemicals. Five
experimental replicates were performed for each treatment and the average number of rearrangements detected per 106 cells per experiment
is shown.
been evaluated for carcinogenic eﬀects, studies performed to
date may not be complete enough to rule out these drugs
as potential cancer-causing agents [96]. Due to the prevalent
usage of hypertensive drugs and the ability of atenolol to
induce fragile site breakage, usage of such drugs may be an
additional risk factor for cancer development, and extensive
investigations are needed.
4.2. Chemotherapeutic Agents. Several chemotherapeutic
agents are known to induce fragile site breakage including
actinomycin D, bleomycin, busulfan, camptothecin, chlo-
rambucil, cytosine arabinoside (cytarabine), 5-azacytidine,
ﬂoxuridine, and methotrexate (Table 1)[ 75, 86]. The
fragile site breakage observed following treatment with these
chemotherapeutic agents was multiplied 3- to 8-fold by the
additionofcaﬀeine.Thesechemotherapeuticsarecommonly
used to treat cancer, including leukemias and lymphomas
(Table 1). Aside from killing cancer cells, residual doses of
chemotherapy drugs can also lead to mutations in healthy
cells that could result in a therapy-related second primary
tumor. The plasma concentrations of cytarabine derived
from the treatment dosage are comparable (∼10μM) or
higher (depending on the regimens) [97],to theamountthat
causes fragile site induction (10μM).
The rate of second primary cancers is on the rise, and
they now account for one in six of all newly diagnosed
cancers in the United States [98]. Thyroid cancer has been
observed as a secondary cancer following treatment for
various cancers, including Hodgkin’s lymphoma [99, 100].
Patients with testicular cancer treated with chemotherapyJournal of Thyroid Research 7
and/or radiation also have a signiﬁcantly elevated risk for
developing thyroid cancer [101]. PTC has been observed in
patients treated for osteosarcoma [57, 102–106], including
children treated with chemotherapeutic agents (some of
whichareknowntoinducefragilesites,includingbleomycin,
actinomycin D, and methotrexate), but not radiation [106].
PTC was documented as a secondary malignancy following
treatment of a pediatric rhabdomyosarcoma patient with
only chemotherapeutic drugs, including actinomycin D
[107]. PTC has also been observed as a second primary
cancer in children treated with chemotherapy alone for
acute lymphoblastic leukemia, neuroblastoma, and Ewing’s
sarcoma [108–111].
Many chemotherapeutic agents target DNA topoiso-
merases, acting as enzymatic poisons and resulting in an
accumulation of double-strand DNA breaks in cells. DNA
topoisomerase I activity is vital for common fragile site
breakage [112, 113]. Camptothecin, one of the fragile-site-
inducing chemotherapeutic agents, is a DNA topoisomerase
I poison. The remaining fragile-site-inducing chemothera-
peutic agents perturb DNA replication and/or RNA tran-
scription in cells, the mode by which many fragile-site-
inducing chemicals lead to chromosomal breakage. Besides
the chemotherapeutic drugs already shown to induce fragile
sites, many others work in a similar manner by inhibiting
DNA topoisomerases and perturbing DNA replication or
RNAtranscription,suggestingadditionaldrugsmayhavethe
ability to induce fragile site breakage.
Together, chemotherapeutic, dietary, and environmental
agents represent a diverse spectrum by which individuals can
be exposed to and increase their risk of fragile site breakage.
Long-term exposure or exposure to signiﬁcant doses of any
of these agents, or a combination of diﬀerent agents, can
increase a person’s susceptibility to cancer development,
including PTC.
5. PTC in Women
The American Cancer Society 2012 report indicated that
the incidence of thyroid cancer among women is three
times higher than men [4]. Thyroid cancer is the fastest-
growing cancer and the sixth most common among women.
Furthermore, the risk of thyroid cancer peaks earlier for
women, where most women are diagnosed in the fourth and
ﬁfth decades of life compared to the sixth and seventh for
men. The rate of PTC among women in the United States
tripled between the early 1980s to the mid-2000s, accounting
for over 75% of all thyroid cancers diagnosed during this
time [3]. Despite this dramatic increase and strong disparity
between women and men, there has been no explanation for
these observations. However, various fragile-site-inducing
factors may contribute to the diﬀerence in PTC incidence in
women versus men (Figure 3).
One possible explanation for this gender disparity is
hormonal diﬀerences between men and women. The num-
bers of chromosomal breaks and sister chromatid exchanges
are elevated in women who are pregnant or taking oral
contraceptives [114–117]. Furthermore, women currently
taking oral contraceptives have an increased incidence of
Smoking
Alcohol
consumption
Others
Workplace
exposure
Hormonal birth
control
Increase in papillary thyroid carcinoma
Figure 3:External fragile-site-inducing/enhancing agents aspoten-
tial risk factors for increased PTC susceptibility in women.
thyroid cancer, including a stronger association with PTC
than other subtypes [118]. Variation in the frequency
of APH-induced common fragile site breakage was also
observed in women during diﬀerent times of the menstrual
cycle, with a signiﬁcant increase during the luteal phase
when progesterone and estradiol levels are at their highest
[119]. Estrogen and progesterone levels ﬂuctuate throughout
the menstrual cycle, but hormonal birth control prevents
ovulation by maintaining consistent hormone levels using
synthetic estrogens and progestins. Since the development of
oral hormonal contraceptives in 1960, the rate of usage has
increased, such that over 10 million women in the United
States ages 15 to 44 years currently take oral contraceptives
[120]. Further, 82% of reproductive-age women have taken
oral hormonal contraceptive pills at some point in their
life. The increasing rate of oral contraceptive use among
teenage girls ages 13 to 18 is particularly striking [121]. The
percentage of women who have ever used high-dose oral
contraceptives (emergency contraception) also rose from
4% to 10% from 2002 to 2008 [120]. The emergency
contraceptive pill Plan B One-step, which contains 1.5mg
of levonorgestrel, a synthetic form of progesterone, has
approximately 10-fold higher levels of the hormone than
traditional contraceptives. These data, combined with the
previous studies that hormone levels aﬀect breakage within
fragile sites, support a possible link between hormonal birth
control use and increased fragile site breakage, but more
work is needed to prove a causative role.
An increasing presence of women in the workforce may
also contribute to elevated incidence of PTC in women. In
1964, only 19 million women in the United States held jobs
outside of the home, compared to 65 million women in8 Journal of Thyroid Research
2010 [122]. During the 1970s and 1980s, employment in
the utility, trade, and transportation industries was most
popular among women, and currently these industries are
ranked second. Working outside of the home, including
commuting to and from work, increases a woman’s exposure
to environmental mutagens such as benzene and diethylni-
trosamine, fragile-site-inducing chemicals found in gasoline
fumes and industrial emissions. Furthermore, exposure to
the same amount of benzene results in approximately 20%
higher levels of benzene metabolites in women versus men
[123], indicating an increased susceptibility to fragile site
breakage in women.
In a study examining cancer incidence in US Air Force
active duty personnel between 1989 and 2002, thyroid cancer
was the third most frequent invasive cancer in women and
four times more prevalent than in the general population
[124]. Of even greater importance, overall cancer rates
among U.S. Air Force personnel were signiﬁcantly reduced
relative to the general population, suggesting occupational
exposure may contribute to the diﬀerence in thyroid cancer
rates. Active duty Air Force personnel encounter unique
occupational exposures that can induce fragile site breakage,
including jet fuel, high altitudes, and chemical weapons.
Trends in cigarette smoking and alcohol consumption
may also contribute to increased PTC among women.
Cigarette smoking has been declining in the United States
over the past several decades, but the rate of decrease varies
between men and women. The number of adult men that
smoke decreased by 11.1% between 1965 to 2009, but the
numberofwomenonlydecreasedby0.5%[125].Ahighlev el
of alcohol consumption among young women is also very
striking. Nearly 66% of women aged 18–44 years consume
alcohol, and 14% binge drink [126]. In 2009, approximately
75% of high school girls reported having drank alcohol
and nearly half currently consumed alcohol, both higher
proportions than in their male counterparts [127]. Also,
between 1979 and 2003 binge drinking among women ages
21–23 dramatically increased—40% among college students
and 20% among nonstudents—compared to a 10% decrease
among men [128]. Alcohol metabolism also diﬀers between
men and women, such that when drinking the same quantity
of alcohol as men, women have a higher blood alcohol
content,whichenhancesthepotentialoffragilesitebreakage.
Due to the signiﬁcant increase in PTC diagnoses among
womeninthepastseveraldecades,especiallyamongyounger
women, it is essential to investigate the mechanisms behind
thistrend.Severalfactors—suchashormonelevels,increased
exposure to environmental agents at the workplace, and
behaviors like cigarette usage and alcohol consumption—
suggest fragile site breakage may contribute to some of the
increased incidence of PTC among women. However, more
work is needed to clarify these risk factors.
6. Conclusion
The dramatic increase of thyroid cancer in the past several
decades is alarming, and it is the fastest-growing cancer
among women. A variety of potential risk factors for thyroid
cancer, including radiation exposure, improved detection
techniques, and obesity, have been proposed. Herein we
provide evidence for an additional risk factor, chromosomal
fragile site breakage. Chromosomal fragile sites are stable
under normal conditions, but DNA breakage at these sites
can be induced through exposure to many external agents.
The genes involved in RET/PTC1 rearrangements, RET and
CCDC6, are located within common fragile sites, and direct
evidence shows that induction of fragile sites results in chro-
mosomal breakage within these genes and ultimately leads
to the formation of RET/PTC1 rearrangements. RET/PTC1
rearrangements are commonly seen in PTC tumors and are
especially represented in case of sporadic PTC. Therefore,
exposure to external fragile-site-inducing conditions could
account for some sporadic PTC tumors and may contribute
to the increase in PTC incidence.
Various external agents can induce fragile site breakage,
including dietary, environmental, and chemotherapeutic
compounds. Furthermore, women are especially susceptible
to many of these agents, and trends over the past several
decades support the involvement of fragile sites in the
increased incidence of PTC in women. Therefore exposure
to external fragile-site-inducing agents, along with genetic
factors, may predispose an individual to PTC development,
making fragile sites an additional potential risk factor for
thyroid cancer. Further work is needed to elucidate the
impact of fragile-site-inducing agents in the formation of
PTC, such that the treatment of patients can be tailored and
further growth in thyroid cancer incidence can be reduced.
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